Study says COVID-19 infection provides immunity, but people can transmit virusPrevious COVID-19 infection provides some immunity for at least five months, but people may still carry and transmit Share XStudy says COVID-19 infection provides immunity, but people can transmit virushttps://pharmaphorum.com/news/study-says-covid-19-infection-provides-immunity-but-people-can-transmit-virus/
Synairgen starts dosing inhaled COVID-19 drug in phase 3 trialUK biotech Synairgen is pushing ahead with a phase 3 trial of SNG001 in hospitalised COVID-19 patients, after Share XSynairgen starts dosing inhaled COVID-19 drug in phase 3 trialhttps://pharmaphorum.com/news/synairgen-starts-dosing-inhaled-covid-19-drug-in-phase-3-trial/
Amgen’s Enbrel heads ICER list of unjustified US price risesUS cost effectiveness watchdog ICER found 10 examples of substantial price rises for top-selling medicines in 2019, and Share XAmgen’s Enbrel heads ICER list of unjustified US price riseshttps://pharmaphorum.com/news/icer-lists-top-unjustified-drug-price-rises-headed-by-amgens-enbrel/
W20 acquires data technology firms Swoop and IPM.aiW20 has begun 2021 by buying data technology firms Swoop and IPM.ai, adding to its rapidly growing list Share XW20 acquires data technology firms Swoop and IPM.aihttps://pharmaphorum.com/news/w20-acquires-data-technology-firms-swoop-and-ipm-ai/
Fishawack Health acquires The Hive Health GroupUK comms agency Fishawack Health has acquired The Hive Health Group and its two brands Hive Health and Share XFishawack Health acquires The Hive Health Grouphttps://pharmaphorum.com/news/fishawack-health-acquires-the/
Hackers posted stolen COVID-19 vaccine info online, says EU regulatorHackers posted stolen confidential information about Pfizer/BioNTech’s COVID-19 vaccine online, the European Medicines Agency has said in an Share XHackers posted stolen COVID-19 vaccine info online, says EU regulatorhttps://pharmaphorum.com/news/hackers-posted-covid-19-vaccine-data-online-says-eu-regulator/
Itamar buys Spry to add wearable to its sleep apnoea detectorsIsraeli company Itamar Medical has agreed to acquire Spry Health, aiming to use the US company’s wearable technology Share XItamar buys Spry to add wearable to its sleep apnoea detectorshttps://pharmaphorum.com/news/itamar-buys-spry-to-add-wearable-to-its-sleep-apnoea-detectors/
IO Biotech raises $155m to develop breakthrough cancer vaccineIO Biotech, an oncology specialist formed and backed by Denmark’s Novo Holdings, has raised €127 million ($155 million) Share XIO Biotech raises $155m to develop breakthrough cancer vaccinehttps://pharmaphorum.com/news/io-biotech-raises-155m-to-develop-breakthrough-cancer-vaccine/
BI investigates cancer ‘dark antigens’ with UK’s EnaraBoehringer Ingelheim has signed a strategic collaboration with UK biotech Enara Bio, focused on finding ways to fight Share XBI investigates cancer ‘dark antigens’ with UK’s Enarahttps://pharmaphorum.com/news/boehringer-to-investigate-dark-antigens-with-uk-cancer-specialist-enara/
Oral COVID-19 vaccine beckons, as ImmunityBio licenses iosBio techImmunityBio has licensed technology underpinning a COVID-19 vaccine that could be administered orally rather than by injection from Share XOral COVID-19 vaccine beckons, as ImmunityBio licenses iosBio techhttps://pharmaphorum.com/news/oral-covid-19-vaccine-beckons-as-immunitybio-licenses-iosbio-tech/
EMA says AstraZeneca’s COVID-19 shot could be approved on 29 JanuaryThe European medicines Agency (EMA) said this morning it has received a marketing application from AstraZeneca for its Share XEMA says AstraZeneca’s COVID-19 shot could be approved on 29 Januaryhttps://pharmaphorum.com/news/ema-says-astrazenecas-covid-19-shot-could-be-approved-on-29-january/
European telehealth firm HealthHero buys MyClinic.ieEuropean telehealth firm HealthHero has bought MyClinic.ie, a rival based in the Republic of Ireland. Already a major Share XEuropean telehealth firm HealthHero buys MyClinic.iehttps://pharmaphorum.com/news/european-telehealth-firm-healthhero-buys-myclinic-ie/
Boehringer, Lilly’s Jardiance ties to match AZ’s Farxiga with heart failure labelBoehringer and Eli Lilly have moved closer to a heart failure indication for their SGLT2 inhibitor Jardiance, as Share XBoehringer, Lilly’s Jardiance ties to match AZ’s Farxiga with heart failure labelhttps://pharmaphorum.com/news/boehringer-lillys-jardiance-ties-to-match-azs-farxiga-with-heart-failure-label/
RNAi biotech Atalanta debuts with $110m plus Biogen and Roche CNS tie-upsUS biotech Atalanta Therapeutics has come out of stealth mode backed with $110m from Biogen and Roche, who Share XRNAi biotech Atalanta debuts with $110m plus Biogen and Roche CNS tie-upshttps://pharmaphorum.com/news/rnai-biotech-atalanta-debuts-with-110m-plus-biogen-and-roche-cns-tie-ups/
bluebird bio to split into oncology and gene therapy specialistsUS biotech bluebird bio has announced plans to split into two this year, with a separate oncology business Share Xbluebird bio to split into oncology and gene therapy specialistshttps://pharmaphorum.com/news/bluebird-bio-to-split-into-oncology-and-gene-therapy-specialists/
Chi-Med agrees R&D partnership with InmageneChina’s Chi-Med and Inmagene Biopharmaceuticals have agreed a strategic partnership to develop preclinical drug candidates for potential treatment Share XChi-Med agrees R&D partnership with Inmagenehttps://pharmaphorum.com/news/chi-med-agrees-rd-partnership-with-inmagene/
Sanofi buys UK’s Kymab and inflammatory disease hopeful for $1.45bnSanofi is to acquire UK biotech Kymab in a deal worth up to $1.45 billion as the big Share XSanofi buys UK’s Kymab and inflammatory disease hopeful for $1.45bnhttps://pharmaphorum.com/news/sanofi-buys-uks-kymab-and-inflammatory-disease-hopeful-for-1-45bn/
Bioclinica boosts digital trial credentials with Saliency buyWith the ink barely dry on its last merger agreement, clinical trial and imaging specialist Bioclinica is on Share XBioclinica boosts digital trial credentials with Saliency buyhttps://pharmaphorum.com/news/bioclinica-boosts-digital-trial-credentials-with-saliency-buy/
Using Define-XML for Dataset Design Share XUsing Define-XML for Dataset Designhttps://pharmaphorum.com/partner-content/using-define-xml-for-dataset-design/
UK Innovators Target Nanoparticles at Inoperable Cancers Share XUK Innovators Target Nanoparticles at Inoperable Cancershttps://pharmaphorum.com/partner-content/uk-innovators-target-nanoparticles-at-inoperable-cancers/
Patient experiences are evolving. How can pharma keep up? Share XPatient experiences are evolving. How can pharma keep up?https://pharmaphorum.com/partner-content/patient-experiences-are-evolving-how-can-pharma-keep-up/
Machine-learning, robotics and biology to deliver drug discovery of tomorrow Share XMachine-learning, robotics and biology to deliver drug discovery of tomorrowhttps://pharmaphorum.com/partner-content/machine-learning-robotics-and-biology-to-deliver-drug-discovery-of-tomorrow/
Prescient Announces Recent Appointments to its Senior Team Share XPrescient Announces Recent Appointments to its Senior Teamhttps://pharmaphorum.com/partner-content/prescient-announces-recent-appointments-to-its-senior-team/
Prescient Announces Recent Appointments to the Senior Advisory Team Share XPrescient Announces Recent Appointments to the Senior Advisory Teamhttps://pharmaphorum.com/partner-content/prescient-announces-recent-appointments-to-the-senior-advisory-team/
